Deal Watch: Pfizer Licenses Cellectis' TALENted CAR-T Candidate
Executive Summary
Array partners with Pierre Fabre to develop and commercialize the MEK and BRAF inhibitors it got from Novartis earlier this year. Astellas buys ophthalmology company Ocata, while divesting dermatology portfolio to Leo Pharma.
You may also be interested in...
Depomed To Make Treasure Out of J&J Trash With Nucynta Buy
Depomed is leveraging all its value to bet on a drug that was virtually ignored by its big pharma owner with its billion-dollar buy of Janssen’s Nucynta.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.